TG Therapeutics Inc (TGTX)
Gross profit margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Gross profit | US$ in thousands | 131,613 | 84,210 | -67,434 | -121,613 | -107,698 |
| Revenue | US$ in thousands | 324,397 | 221,047 | 2,785 | 6,689 | 152 |
| Gross profit margin | 40.57% | 38.10% | -2,421.33% | -1,818.10% | -70,853.95% |
December 31, 2024 calculation
Gross profit margin = Gross profit ÷ Revenue
= $131,613K ÷ $324,397K
= 40.57%
TG Therapeutics Inc's gross profit margin experienced significant fluctuations over the years. The company reported negative margins in the range of -70,853.95% to -1,818.10% in the fiscal years ending December 31, 2020, and December 31, 2021, indicating that the cost of goods sold exceeded the revenues generated from sales by a substantial margin.
However, there was a notable improvement in the gross profit margin for the fiscal years ending December 31, 2022, December 31, 2023, and December 31, 2024, with margins of -2,421.33%, 38.10%, and 40.57%, respectively. These positive margins suggest that the company was able to effectively control its production costs and generate higher revenues from its sales.
The transition from negative to positive gross profit margins indicates a potential improvement in the company's operational efficiency and sales performance. It is essential for TG Therapeutics Inc to continue monitoring and managing its cost structure to sustain this positive trend and enhance overall profitability in the future.
Peer comparison
Dec 31, 2024